Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT00222469
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    10mg/kg IV on Day 1 Q 2 weeks
  • gemcitabine — DRUG
    1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
  • oxaliplatin — DRUG
    100mg/m2 on Day 2 and Q 2 weeks.

Study Details

The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival. In addition, the study will find out what side effects patients may have by taking bevacizumab, oxaliplatin, and gemcitabine together.

Key Dates

First listed
Sep 22, 2005
Start date
Aug 31, 2005
Status verified
Jul 2008
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
50 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: 1
    3-agent treatment group

Primary Outcome Measure

To determine the overall survival (OS) rate at 1 year in this patient population, treated with the combination therapy of bevacizumab plus gemcitabine and oxaliplatin [ Time Frame: One year ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of OklahomaOklahoma CityOklahoma73104-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Oklahoma City, OK

By research site
University of Oklahoma· Oklahoma City, OKMD Anderson Cancer Center· Houston, TX

Related Studies